Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruno Brochet

Showing results (81-90 of 120) with videos related to

Pageof 12
Sort By:
Annals of Neurology|April 3, 2008
Predicting progression in primary progressive multiple sclerosis: a 10-year multicenter studyZhaleh Khaleeli, Olga Ciccarelli, Francesco Manfredonia, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 24, 2024
Konectom™ cognitive processing speed test enables reliable remote, unsupervised cognitive assessment in people with multiple sclerosis: Exploring the use of substitution time as a novel digital outcome measureMatthew Scaramozza, Patrizia A Chiesa, Lauren Zajac, et al.
Multiple Sclerosis and Related Disorders|January 22, 2019
First clinical inflammatory demyelinating events of the central nervous system in a population aged over 70 years: A multicentre studyNoëlle Lavandier, Mickaël Bonnan, Clarisse Carra-Dallière, et al.
Neurodegenerative Disease Management|December 16, 2024
Improvements in quality of life of people with relapsing multiple sclerosis treated with cladribine tablets during the 2-year CLARIFY-MS study: a plain language summaryBruno Brochet, Alessandra Solari, Jeannette Lechner-Scott, et al.
The Lancet. Neurology|November 1, 2020
Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trialJerry S Wolinsky, Douglas L Arnold, Bruno Brochet, et al.
Frontiers in Neurology|June 7, 2021
Prevalence, Severity, and Clinical Management of Brain Incidental Findings in Healthy Young Adults: MRi-Share Cross-Sectional StudyAïcha Soumaré, Naka Beguedou, Alexandre Laurent, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 26, 2016
Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disordersAlexis Montcuquet, Nicolas Collongues, Caroline Papeix, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 18, 2023
Improvements in quality of life over 2 years with cladribine tablets in people with relapsing multiple sclerosis: The CLARIFY-MS studyBruno Brochet, Alessandra Solari, Jeannette Lechner-Scott, et al.
Journal of Clinical Apheresis|May 6, 2020
Double-blind, randomized controlled trial of therapeutic plasma exchanges vs sham exchanges in moderate-to-severe relapses of multiple sclerosisBruno Brochet, Mathilde Deloire, Christine Germain, et al.
Neurology|July 22, 2020
Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extensionStephen L Hauser, Ludwig Kappos, Douglas L Arnold, et al.
Pageof 12

Showing results (81-90 of 120) with videos related to

Sort By:
Pageof 12
Annals of Neurology|April 3, 2008
Predicting progression in primary progressive multiple sclerosis: a 10-year multicenter studyZhaleh Khaleeli, Olga Ciccarelli, Francesco Manfredonia, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 24, 2024
Konectom™ cognitive processing speed test enables reliable remote, unsupervised cognitive assessment in people with multiple sclerosis: Exploring the use of substitution time as a novel digital outcome measureMatthew Scaramozza, Patrizia A Chiesa, Lauren Zajac, et al.
Multiple Sclerosis and Related Disorders|January 22, 2019
First clinical inflammatory demyelinating events of the central nervous system in a population aged over 70 years: A multicentre studyNoëlle Lavandier, Mickaël Bonnan, Clarisse Carra-Dallière, et al.
Neurodegenerative Disease Management|December 16, 2024
Improvements in quality of life of people with relapsing multiple sclerosis treated with cladribine tablets during the 2-year CLARIFY-MS study: a plain language summaryBruno Brochet, Alessandra Solari, Jeannette Lechner-Scott, et al.
The Lancet. Neurology|November 1, 2020
Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trialJerry S Wolinsky, Douglas L Arnold, Bruno Brochet, et al.
Frontiers in Neurology|June 7, 2021
Prevalence, Severity, and Clinical Management of Brain Incidental Findings in Healthy Young Adults: MRi-Share Cross-Sectional StudyAïcha Soumaré, Naka Beguedou, Alexandre Laurent, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 26, 2016
Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disordersAlexis Montcuquet, Nicolas Collongues, Caroline Papeix, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 18, 2023
Improvements in quality of life over 2 years with cladribine tablets in people with relapsing multiple sclerosis: The CLARIFY-MS studyBruno Brochet, Alessandra Solari, Jeannette Lechner-Scott, et al.
Journal of Clinical Apheresis|May 6, 2020
Double-blind, randomized controlled trial of therapeutic plasma exchanges vs sham exchanges in moderate-to-severe relapses of multiple sclerosisBruno Brochet, Mathilde Deloire, Christine Germain, et al.
Neurology|July 22, 2020
Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extensionStephen L Hauser, Ludwig Kappos, Douglas L Arnold, et al.
Pageof 12